Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | UGCG | Q16739 | 1/20 | 0.51 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 7/20 | 0.47 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6551488 | 1.00 | L3MBTL1 (0.65) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL27089915 | 1.00 | L3MBTL1 (0.65) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL16614410 | 1.00 | L3MBTL1 (0.65) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL9234752 | 0.98 | L3MBTL1 (0.62) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL4483666 | 0.93 | L3MBTL1 (0.59) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL29285378 | 0.90 | L3MBTL1 (0.56) | L3MBTL1TDP1GBA1UGCGGBA2 | |
| SCHEMBL18682485 | 0.86 | LTA4H (0.49) | L3MBTL1TDP1APPHTTMEN1 | |
| SCHEMBL18682483 | 0.86 | LTA4H (0.49) | L3MBTL1TDP1APPHTTMEN1 | |
| SCHEMBL4741980 | 0.85 | TDP1 (0.54) | L3MBTL1TDP1CA1CA2APP | |
| SCHEMBL1354132 | 0.85 | L3MBTL1 (0.56) | L3MBTL1TDP1GBA1UGCGGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146262-A | Bi-phosphatidyl amide compound containing multiple tertiary amino structures, composition and application thereof | 北京大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-2537854-B1 | METHOD FOR PRODUCING 18F-LABELED COMPOUND AND HIGH MOLECULAR COMPOUND TO BE USED IN THE METHOD | TOKYO INST TECH (JP) | 2016-12-14 | — | — | EP | disclosed |
| EP-2537854-B1 | METHOD FOR PRODUCING 18F-LABELED COMPOUND AND HIGH MOLECULAR COMPOUND TO BE USED IN THE METHOD | TOKYO INST TECH (JP) | 2016-12-14 | — | — | EP | disclosed |
| US-9073802-B2 | Method for producing 18F-labeled compound and high molecular compound to be used in the method | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9073802-B2 | Method for producing 18F-labeled compound and high molecular compound to be used in the method | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9073802-B2 | Method for producing 18F-labeled compound and high molecular compound to be used in the method | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-2280935-B1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-10-15 | — | — | EP | disclosed |
| EP-2268606-B1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8673946-B2 | 4-trimethylammonio-butyrates as CPT2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130030033-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2013-01-31 | — | — | US | disclosed |
| EP-2537854-A1 | METHODE FOR PRODUCING F-LABELLED COMPOUND AND HIGH MOLECULAR COMPOUND TO BE USED IN THE METHOD | Tokyo Institute of Technology (JP) | 2012-12-26 | — | — | EP | disclosed |
| EP-2537854-A1 | METHODE FOR PRODUCING F-LABELLED COMPOUND AND HIGH MOLECULAR COMPOUND TO BE USED IN THE METHOD | Tokyo Institute of Technology (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | ANDJELKOVIC MIRJANA (CH) | 2012-11-15 | — | — | US | disclosed |
| WO-2011099480-A1 | METHOD FOR PRODUCING 18F-LABELED COMPOUND AND HIGH MOLECULAR COMPOUND TO BE USED IN THE METHOD | 国立大学法人東京工業大学 (JP) | 2011-08-18 | — | — | WO | disclosed |
| EP-2280935-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| EP-2268606-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009132979-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132978-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270500-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | L3MBTL1 1452/4885TDP1 2013/4885GBA1 915/4885 |
| US-20090270500-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | CPT1A, CPT1B, CPT2 | L3MBTL1 1676/4885TDP1 2520/4885GBA1 1705/4885 |
| US-20120289554-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | L3MBTL1 1452/4885TDP1 2013/4885GBA1 915/4885 |
| US-20130030033-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | CPT1A, CPT1B, CPT2 | L3MBTL1 1676/4885TDP1 2520/4885GBA1 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.